Theranostics: 68GaDOTATOC and 90YDOTATOC (PRRT)

Participants in this research study have tumors that express somatostatin receptors such as a neuroendocrine tumor, medulloblastoma, meningioma, and neuroblastoma. The purpose of this research study is to determine if 90Y-DOTATOC is an effective treatment for tumors that express somatostatin receptors and if 68Ga-DOTATOC PET/CT can measure the extent of disease and measure response to this therapy. This research will determine if this process called dosimetry is an effective technique to determine how much 90Y-DOTATOC the participants can safely receive without damage to their kidneys and bone marrow.

NCT: NCT02441088

Locations: University of Iowa Hospitals and Clinics

Link: https://clinicaltrials.gov/ct2/show/NCT02441088?recrs=ad&cond=Neuroblastoma&locn=University+of+Iowa&cntry=US&age=0&draw=2&rank=3